The Social Security Administration (SSA) released a new publication to help individuals living with sickle cell disease understand and...

Exciting news! A new and improved Parent and Caregiver Handbook for Sickle Cell is available in English and Spanish. This comprehensive...

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) announced today that it is voluntarily withdrawing all lots of OXBRYTA ® (voxelotor)...

(Ontario, CA) – The Sickle Cell Disease Foundation (SCDF) is rallying communities, health care providers, and policymakers to recognize...

Despite cutting-edge treatments, many patients—mainly Black and brown—don’t even get basic support.

PAINFULLY AWARE: Understanding Sickle Cell and Its Impact on The African American Community

After living with sickle cell disease for 39 years, I’m both excited and skeptical about the newly approved gene therapies 

December 8, 2023. Today the U.S. Food and Drug Administration approved two milestone treatments, Casgevy and Lyfgenia, representing the...

The U.S.Food and Drug Administration (FDA)approvedNovartis’ Adakveo (crizanlizumab) to decrease the frequency of vaso-occlusive crises...

Oxbryta (voxelotor), a first sickle cell treatment that works to stop the sickling and destruction of red blood cells that mark this...

The Networking California for Sickle Cell Care Initiative (NCSCC) was developed through advocacy and stakeholder engagement supported by...